lomustine Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Lomustine is used in the treatment of certain neoplastic diseases. Although it is generally agreed that lomustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. Common adverse reactions include delayed myelosupression, nausea, vomiting, stomatitis, and alopecia.   NCATS

Chemistry

  • SMILES: ClCCN(N=O)C(=O)NC1CCCCC1
  • InChIKey: GQYIWUVLTXOXAJ-UHFFFAOYSA-N
  • Mol. Mass: 233.695
  • ALogP: 2.25
  • ChEMBL Molecule:
    lomustine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea | 1-(2-chloroethyl)-3-cyclohexylnitrosourea | belustine | ccnu | cecenu | ceenu | chloroethylcyclohexylnitrosourea | cinu | cyclohexyl chloroethyl nitrosourea | lomustin | lomustina | lomustine | lomustinum | n-(2-chloroethyl)-n'-cyclohexyl-n-nitrosourea

Organizations (123)

Research & Development (121)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (37)

Approved Indications (2)


 

Brain Neoplasms (approved 1976)

Hodgkin Disease (approved 1976)

Experimental Indications - Clinical Trial Phases 1-4 (37)


 

Astrocytoma (Phase 3)

Bone Marrow Diseases (Phase 1)

Bone Neoplasms (Phase 1/Phase 2)

Brain Neoplasms (Phase 3)

Breast Neoplasms (Phase 1/Phase 2)

Central Nervous System Neoplasms (Phase 3)

Cognition Disorders (Phase 3)

Colorectal Neoplasms (Phase 1/Phase 2)

Diffuse Intrinsic Pontine Glioma (Phase 2)

Disability Evaluation (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 1)

Ependymoma (Phase 2)

Genes (Phase 2)

Geriatrics (Phase 3)

Glioblastoma (Phase 3)

Glioma (Phase 3)

Gliosarcoma (Phase 3)

Hodgkin Disease (Phase 2)

Kidney Neoplasms (Phase 1/Phase 2)

Leukemia, Myeloid, Acute (Phase 3)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, AIDS-Related (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1/Phase 2)

Lymphoma, T-Cell (Phase 1/Phase 2)

Medulloblastoma (Phase 3)

Melanoma (Phase 2)

Multiple Myeloma (Phase 3)

Neoplasm Metastasis (Phase 1/Phase 2)

Neoplasms (Phase 1/Phase 2)

Oligodendroglioma (Phase 3)

Pancreatic Neoplasms (Phase 1/Phase 2)

Sarcoma (Phase 1/Phase 2)

Spinal Cord Neoplasms (Phase 2)

Stomach Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 97
  • # of Trial Organizations: 121

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue